Skip to main content

Table 1 Distributions of concentrations of urinary metabolites of organophosphate flame retardants (ng/ml; specific gravity-corrected) in female papillary thyroid cancer cases and controls

From: A case-control study of exposure to organophosphate flame retardants and risk of thyroid cancer in women

Flame retardant MDL % Detected Cases (n = 100) Controls (n = 100)
Median 25th–75th Percentile Median 25th–75th Percentile
BCIPP 0.185 44.5 0.242 <MDL – 0.280 <MDL <MDL – 0.705
DPHP 0.104 97 0.802 0.457–1.549 0.843 0.506–1.450
BDCIPP 0.046 97.5 0.729 0.344–1.777 0.604 0.276–1.336
ipPPP 0.020 100 2.569 1.361–4.758 2.251 1.300–4.201
BCIPHIPP 0.001 99.5 0.160 0.084–0.377 0.214 0.093–0.564
  1. bis(1-chloro-2-propyl)1-hydroxy-2-propyl phosphate (BCIPHIPP), bis(1-chloro-2-propyl) phosphate (BCIPP), diphenyl phosphate (DPP), bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), isopropyl-phenyl phenyl phosphate (ip-PPP), and tert-butyl phenyl phenyl phosphate (tb-PPP), MDL (method detection limit)